Christian Rutzer: Roche and Novartis – Basel’s Research and Innovation Powerhouses
Christian Rutzer, Deputy Head and Lead Scientist at the CIEB University of Basel, shared on LinkedIn:
“๐๐จ๐๐ก๐ ๐๐ง๐ ๐๐จ๐ฏ๐๐ซ๐ญ๐ข๐ฌ: ๐๐๐ฌ๐๐ฅ’๐ฌ ๐๐๐ฌ๐๐๐ซ๐๐ก and ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง ๐๐จ๐ฐ๐๐ซ๐ก๐จ๐ฎ๐ฌ๐๐ฌ
Both research and innovation (R and I) are key drivers of a successful drug pipeline. With this in mind, we at the CIEB Universitรคt Basel analyzed the quality of large pharmaceutical companies’ R&I activities. Here are our key findings:
– Basel-based Roche is very strong in R adn I, as evidenced by a much higher than average number of citations per scientific paper and patent. Basel-based Novartis is also above average on both counts.
– Amgen, Gilead Sciences, Astra Zeneca, and Bristol Myers Squibb also have both highly cited scientific papers and patents. Amgen in particular has received many citations for its patents.
– Novo Nordisk, Pfizer, Bayer, and Glaxo Smith Kline have highly cited scientific papers but not as many highly cited patents.
In summary, our analysis confirms that Basel-based Roche and Novartis are among the leaders in producing highly cited and influential R and I. These results point to a positive future for Basel in drug development and healthcare innovation.
Notes: Data include company affiliations. For example, Genentech is assigned to Roche. We used all USPTO patents and scientific papers from the Scopus database attributed to the pharmaceutical field between 2013 and 2022. For patents, we used docdb family citations, and for papers, we weighted citations by author (as papers often contain a larger number of authors from different institutions).”
Source: Christian Rutzer/LinkedIn